[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"crohns-disease-relapse\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:crohns-disease-relapse":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100558587","acupuncture-reduces-relapse-in-patients-with-crohns-disease-a-superiority-trial-100558587",false,"NCT06553053","Acupuncture Reduces Relapse in Patients With Crohn's Disease: a Superiority Trial","Inclusion Criteria:\n\n1. patients with clinical diagnosis consistent with CD;\n2. aged 16-75;\n3. patients in remission (CDAI \\\u003C 150 and CRP \\\u003C 5mg\u002Fl, or Faecal calprotectin \\\u003C 50μg\u002Fg, or no ulcer under endoscopy);\n4. patients with frequent disease recurrences (≥2) in the past years;\n5. patients were not taking medication or were only taking one or more of the following drugs: \\[mesalazine (≤4g\u002Fd), prednisone (≤15mg\u002Fd), azathioprine (≤1mg\u002Fkg\u002Fd)\\] and prednisone and mesalazine were used for at least 1 month, while azathioprine was used for at least 3 months; or those who had poor response or loss of response to biological preparations (anti-TNF-α, IL-12p40, α4β7);\n6. those who have never experienced acupuncture;\n7. patients signing informed consent.\n\nExclusion Criteria:\n\n1. patients who are recently pregnant or in pregnancy or lactation;\n2. patients with serious organic diseases;\n3. patients diagnosed as psychosis;\n4. patients who suffer from multiple diseases and need to take other drugs for a long time, and may affect the observation of the efficacy of this trial;\n5. severe skin diseases (such as erythema nodosum, pyoderma gangrenosum, etc.), eye diseases (such as iritis, uveitis, etc.), thromboembolic diseases and other serious extraintestinal manifestations;\n6. there are serious intestinal fistula, abdominal abscess, intestinal stenosis and obstruction, perianal abscess, gastrointestinal hemorrhage, intestinal perforation and other complications;\n7. patients with short bowel syndrome who have undergone abdominal or gastrointestinal surgery in the past half a year;\n8. there are skin diseases or defects in the selected area of acupuncture and moxibustion that cannot be performed.","ALL","16 Years","75 Years",{"count":19,"type":20},106,"ESTIMATED","INTERVENTIONAL",[23],"NA","The aim of this study was to further improve the clinical efficacy of acupuncture in delaying the clinical recurrence of CD and to explore the efficacy mechanism of acupuncture efficacy enhancement.",[26,27],"Crohn's Disease Relapse","Inflammatory Bowel Diseases","RECRUITING","2026-04-07",{"date":31,"type":32},"2026-04-13","ACTUAL",{"date":34,"type":32},"2024-08-13",{"date":36,"type":20},"2028-12-31",{"name":38,"class":39},"Shanghai Institute of Acupuncture, Moxibustion and Meridian","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100485305","phase-2-pre-treatment-with-azithromycin-to-reduce-immunogenicity-to-to-anti-tnf-agents-in-patients-with-crohns-disease-100485305","NCT05599347","Pre-treatment With Azithromycin to Reduce Immunogenicity to to Anti-TNF Agents in Patients With Crohn's Disease","Pre-treatment With Azithromycin to Reduce Immunogenicity to Anti-Tumor Necrosis Factor-α Agents in Patients With Crohn's Disease","AZITRATIM","Inclusion Criteria:\n\n* Ability to provide written informed consent prior to any study procedures and willing and able to attend all study visits, comply with the study procedures, read and write in order to complete questionnaires, and be able to complete the study period.\n* Aged 18 to 80 years of age, inclusive, at the time of signing the informed consent.\n* Diagnosis of CD with an onset of symptoms for a minimum of 3 months prior to Screening as determined by the investigator based on clinical history, exclusion of infectious causes, and characteristic endoscopic and histologic findings.\n* Prior decision of starting infliximab or adalimumab therapy (including biosimilar drugs).\n* Thiopurine and corticosteroid co-therapy will be permitted.\n\nExclusion Criteria:\n\n* Inclusion in another interventional study\n* Patients who cannot provide informed consent and do not have a legal guardian\n* Patients with perianal involvement who are expected to require antibiotic therapy for their disease\n* Patients on chronic antibiotic therapy due to any cause\n* Patients with ongoing fluid collection\u002Fabscess either internal or perianal\n* Known history of allergy to the study intervention formulation or any of its excipients or components of the delivery device\n* Prolonged QTc interval or conditions leading to additional risk for QT prolongation\n* Chronic kidney disease stage 5 (GFR \\\u003C 10)\n* Crohn's Disease complication requiring surgical treatment\n* Planned\u002Fongoing methotrexate co-therapy\n* Fecal microbiota transplantation within 8 weeks prior to randomization\n* Participant has any disorder that, in the opinion of the investigator, may compromise the ability to participate in the study\n* Pregnancy\n* Patients who received azithromycin therapy in the previous year (we will not exclude prior use of other antibiotic therapy)\n* Patients who received any antibiotic treatment within 4 weeks prior to randomization\n* Re-induction of the same anti-TNF medication\n* Patients who are on chronic therapy which cannot be withheld in one of these medications: colchicine, phenytoin, and digoxin","18 Years",{"count":51,"type":20},180,[53],"PHASE2","This is a randomized placebo-controlled trial in Crohn's disease patients before initiation of anti-tumor necrosis factor-α (anti-TNF) therapy that aims to test the effect of a pre-treatment short course of azithromycin therapy on immunogenicity",[26,56],"Biological Substance; Adverse Effect",[58,59,60,61,62],"Crohn's disease","infliximab","adalimumab","azithromycin","immunogenicity","2025-04-02",{"date":65,"type":32},"2025-04-04",{"date":67,"type":32},"2023-04-24",{"date":69,"type":20},"2026-12-31",{"name":71,"class":39},"Rambam Health Care Campus",9]